stockrow
Friday 6 November 2026
Export ERAS’s income statement to Excel — free account
Erasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
14.34
1.07
+8.06%
Follow ERAS
Alert me
Erasca, Inc. (ERAS) Debt to equity
Erasca, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 0.0×, down 0.0× from fiscal 2025 (0.0×). Over the past ten years it has ranged from 0.0× (fiscal 2025) to 0.1× (fiscal 2019) — the current reading is the lowest in ten years. That is in line with the Biotechnology industry median of 0.0× and in line with the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.1× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 21 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.1×
Ten-year median
0.0×
Current reading's percentile
86
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | 0.0× |
| ERAS Erasca, Inc. | 0.0× |
| DNTH Dianthus Therapeutics, Inc. compare | 0.0× |
| MANE Veradermics Incorporated compare | 0.0× |
| DFTX Definium Therapeutics, Inc. compare | 0.0× |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 0.1× |
| CRSP CRISPR Therapeutics AG compare | 0.4× |
| COGT Cogent Biosciences, Inc. compare | 0.4× |
| TVTX Travere Therapeutics, Inc. compare | 26.7× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)